investigated the therapeutic effect of IRE-ablation combined with PD-1/CTLA4 blockades in an endogenous TA SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cell-1)-expressing TRAMP-C2 prostate cancer (5–6 mm) model, and found that the combined IRE-ablation protocol stimulated SPAS-1-specific CD8+ T cell responses and led to sustained tumor remission but not eradication (61). Here, CD8A is linked to prostate carcinoma.